Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies
Authors:
Open Access
- 12 January 2023
- journal article
- research article
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (2) , 585-596
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive GlioblastomaJAMA Oncology, 2017
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyNew England Journal of Medicine, 2016
- NeuroblastomaNature Reviews Disease Primers, 2016
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive SarcomaJournal of Clinical Oncology, 2015
- Inhibition of endothelial ERK signalling by Smad1/5 is essential for haematopoietic stem cell emergenceNature Communications, 2014
- Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastomaBlood, 2011
- Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapyGene Therapy, 2011
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Intrapleural Infusion of Activated Macrophages and γ-Interferon in Malignant Pleural MesotheliomaChest, 2002